Kornimate/medical-research-clean huggingface dataset:
high pressure balloon vs cutting balloon

Conditions: End Stage Renal Failure on Dialysis

Summary: patients suspected of having av access stenosis will be referred to the division of vascular and endovascular surgery by the dialysis center. patients with signs of av access failure who are found to have significant stenosis (more than 50%) at the venous end of the anastomosis will then be randomized to either high pressure balloon (conquest) or to a cutting balloon (boston scientific balloon). angiograms will then be performed before and after intervention.

patients suspected of having av access stenosis will be referred to the division of vascular and endovascular surgery by the dialysis center. patients with signs of av access failure who are found to have significant stenosis (more than 50%) at the venous end of the anastomosis will then be randomized to either high pressure balloon (conquest) or to a cutting balloon (boston scientific balloon). angiograms will then be performed before and after intervention. data will be collected from standard of care visit, including physician visits and ultrasounds. follow up will be based on the function of the av access, dialysis center criteria and/or standard of care ultrasound results: including venous pressure of the av access, difficult cannulation, urea recirculation, and change in character and sound of the av access (thrill/bruit), which are standard of care assessment at a dialysis center. all patient data sheets will be kept in a study binder and locked in the research room. randomization will be performed with a computer program.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years of age 2. av fistula or graft 3. undergoing weekly hemodialysis 4. patients must agree to the terms of the study and sign an informed consent exclusion criteria: 1. pregnant women
hf patients with lvads being treated with sglt2i

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: the main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (sglt2i) in heart failure (hf) patients with left ventricular assist devices (lvad).

the exact mechanism of cardiovascular benefit from sglt2i continues to be the source of further research. the investigators hypothesize that heart failure patients with lvads will similarly benefit from the sglt2i-associated natriuresis and diuresis, which in turn reduces preload. this is further associated with reduced heart failure readmissions and right ventricular failure. additionally, the animal models indicating reduced cardiac work and remodeling in this population may benefit these patients as one of the goals of lvad implantation is to reduce cardiac energy expenditure and promote remodeling and recovery in these patients. this is a prospective, randomized controlled study to assess cardiac benefit of sglt2i in 40 consecutive patients with heart failure undergoing lvad implantation. after routine lvad implantation, patients will be randomized 1:1 to one of two routine care arms: management with an sglt2i \[empagliflozin 10 milligram (mg) daily or dapagliflozin 10 mg daily, based on formulary coverage\] or no sglt2i. the patient's treating physician will be able to override randomization assignment if they determine that the assignment is not in the patient's best interest. sglt2i management (if applicable) and follow-up care will be dictated by routine care. data will be collected from the subject's medical record for 6 months.

Eligibility criteria:
inclusion criteria: 1. lvad implantation 2. have not already been prescribed management with an sglt2i 3. estimated glomerular filtration rate (egfr) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2 4. age ≥ 18 years-old 5. able to provide informed consent exclusion criteria: 1. diagnosis of type 1 diabetes mellitus 2. egfr \< 30 ml/min/1.73 m2 3. age \< 18 years-old

Keywords: left ventricular assist device sglt2i
motor imagery in rehabilitation after a distal radius fracture

Conditions: Distal Radius Fracture

Summary: the aim of this study is to determine whether motor imagery training during the immobilisation period in patients with a distal radius fracture, results in an improved functional outcome compared to patients who do not perform motor imagery.

rationale: distal radius fracture (drf) is a common injury that may lead to prolonged function restrictions, decreased range of motion, reduced grip strength and pain. these symptoms may be caused by physical changes due to the injury and/or by the 4-6 weeks immobilization that is part of the conservative treatment. however, it might also be that neural changes during the immobilization play an important role. such changes might be prevented by motor imagery training during the immobilization period. so, when neural changes are prevented, this may lead to a better functional outcome. objective: the objective is to improve the functional outcome in distal radius fracture patients, specified as an increase in function, dexterity, grip strength, range of motion, and decrease of pain. study design: parallel group randomized controlled trial, with a post-test only control group design. patients in the experimental group perform motor imagery training during the immobilization period, in addition to the regular treatment. patients in the control group receive regular treatment. study population: female drf-patients who are conservatively treated by a cast, aged 45-75 years. the fracture must be a low energy trauma caused by a fall. patients with a score higher than 72 on the vividness of motor imagery questionnaire (vmiq) are excluded, as well as patients with co-morbidities that might influence the wrist function, or motor imagery-ability, and patients with no understanding of dutch language. the patients are randomly allocated to the experimental or control group by restricted randomization to ensure equal group sizes. intervention: motor imagery training during the immobilization period). main study parameters/endpoints: the main study parameter is function. secondary study parameters are dexterity, range of motion, grip strength, and pain.

Eligibility criteria:
inclusion criteria: * female patients * non-comminutive distal radius fracture * 45 to 75 years of age exclusion criteria: * distal radius fracture caused by het * comorbidities possibly influencing wrist function * comorbidities possibly influencing motor imagery ability * score higher than 72 on the vividness of motor imagery questionnaire

Keywords: distal radius fracture motor imagery immobilisation effectivity
atomoxetine for treating attention deficit hyperactivity disorder in young children

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: this study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (adhd) in young children.

attention deficit hyperactivity disorder (adhd) is one of the most common mental disorders in children. children with adhd often have impaired functioning in home and school and usually experience difficulty relating to peers. if left untreated, the disorder can have long-term adverse effects into adolescence and adulthood. atomoxetine is a selective noradrenergic reuptake inhibitor that is fda-approved for the treatment of adhd in children, adolescents, and adults. unlike most other medications for adhd, atomoxetine is not a stimulant. studies have shown that atomoxetine is effective in treating adhd, but more information is needed on its effectiveness in young children. this study will evaluate the effectiveness of atomoxetine in reducing the symptoms of adhd in young children. participants in this double-blind study will be randomly assigned to receive either atomoxetine or placebo for 8 weeks. in addition, all children will receive parent training for the duration of the study. for the first 5 weeks, participants will report to the study site weekly for assessments of adhd symptoms. study visits will occur every other week for the remainder of the study.

Eligibility criteria:
inclusion criteria: * parent and child must be english speaking * child has been living with parent/guardian for at least six months * meets criteria for adhd on the disc, on clinical interview, and on clinical consensus conference * adhd is primary disorder with symptoms present for at least 9 months * adhd-iv-rating scale (adhd-iv-rs)score that is at least 1.5 standard deviations above age and sex norms * score of 55 or below on the children's global assessment scale * score of 4 or greater on the clinical global impression scale * estimated intelligence quotient (iq) of 70 or greater * currently participating in school at least 2 half-days per week * able to identify a teacher who can make valid assessments * patient and parent are able to attend regular study visits exclusion criteria: * currently taking other psychotropic medications or other medications with effects on the central nervous system * currently being treated effectively with atomoxetine * major medical conditions that might interfere with study medications * history of or current clinically significant kidney illness * evidence of adjustment disorder, autism, psychosis, bipolar disorder, suicide ideations, or any other psychiatric disorder requiring treatment with additional psychotropic medication * history of physical, sexual, or emotional abuse impacting clinical presentation * prior failure to respond to an adequate trial of atomoxetine

Keywords: adhd atomoxetine
korea university anam hospital optical coherence tomography registry

Conditions: Coronary Artery Disease; Optical Coherence Tomography

Summary: all comer registry who had undergone intravascular optical coherence tomography during and/or after coronary intervention.

optical coherence tomography registry is composed with before coronary stenting, immediate after coronary stenting and follow-up study.

Eligibility criteria:
inclusion criteria: * patients who had undergone coronary intervention and optical coherence tomography exclusion criteria: * none
energetics and function in older humans

Conditions: Aging; Erythrocyte Glutathione Deficiency; Muscle Weakness

Summary: the investigators have previously reported that older patients with hiv are deficient in glutathione (gsh) due to decreased availability of cysteine and glycine, and that oral supplementation with cysteine (as n-acetylcysteine) and glycine for 2-weeks corrects their own levels, and improves concentrations of red-cell gsh. the investigators also found that when gsh deficient, subjects had impaired mitochondrial energetics and this improved with an increase in intracellular gsh concentrations. the current proposal will investigate if cysteine and glycine supplementation for a duration of 24 weeks will result in changes in : (a) gsh levels; (b) body composition/anthropometry; (c) strength and function; (d) quality of life; (e) mitochondrial energetics; (f) biochemistry (including dyslipidemia and oxidative stress); (g) protein and glucose metabolism; (h) cognition and memory. 3 months after completing supplementation, measurement of gsh concentrations, strength, function, mitochondrial energetics and neurocognitive tests will be done to determine the effects of washout.

data not available at present

Eligibility criteria:
inclusion criteria: older subjects: * age 70-80 years; younger subjects: * age 21-30 years exclusion criteria: 1. no known diabetes, liver disease, kidney disease, coronary heart disease, stroke, or cancer; 2. any limitations in ability to walk; 3. triglyceride concentrations greater than 500 mg/dl (if lipid lowering medications are stopped); 4. bmi less than 20.
pilot study of secondary causes of osteopenia/osteoporosis in adults with breast and prostate cancer

Conditions: Breast Cancer; Prostate Cancer; Osteopenia; Osteoporosis

Summary: the investigators hypothesis is that secondary causes of bone loss are prevalent in patients with breast and prostate cancer, and those patients with secondary causes of bone loss are at higher risk for treatment related bone loss. the goals of this pilot study are to estimate the prevalence of secondary causes of osteoporosis in a cohort of patients with nonmetastatic breast and prostate cancer with osteopenia and osteoporosis.

the interaction of aging, cancer, and bone loss is poorly understood. cancer or cancer therapy could potentially accelerate bone loss and increase the risk for osteopenia or osteoporosis. the hypothesis of this observational study is that secondary causes of bone loss are prevalent in patients with breast and prostate cancer who are high risk for treatment related bone loss. in order to test this hypothesis, this prospective pilot study will systematically evaluate secondary causes of bone loss in a cohort of patients with nonmetastatic breast and prostate cancer with osteopenia/osteoporosis. 1. identify patients with nonmetastatic breast cancer newly diagnosed with osteopenia/osteoporosis (dual energy x-ray absorptiometry bone density scan t-score average between hip (femoral neck) and spine (l1-l4) of less than -1.0 to -2.5/ less than -2.5, respectively). 2. identify patients with nonmetastatic prostate cancer newly diagnosed with osteopenia/osteoporosis (dual energy x-ray absorptiometry bone density scan t-score average between hip (femoral neck) and spine (l1-l4) of less than -1.0 to -2.5/ less than -2.5, respectively). 3. refer patient to city of hope endocrinology osteoporosis clinic. 4. approach patient in consecutive order in which they have been referred to endocrinology osteoporosis clinic. 5. describe the study to the patient: patient consents or refuses. 6. once consented, the patient's medical records are reviewed and dual energy x-ray absorptiometry bone density reports are obtained from city of hope records or the screening medical institution records to confirm diagnosis of osteopenia/osteoporosis or normal bone health. 7. study participants will undergo an evaluation for secondary causes of bone per standard of care with patient questionnaires. 8. furthermore, laboratory tests that support secondary causes of bone loss will be retrospectively collected via chart review.

Eligibility criteria:
inclusion criteria 1. diagnosis of nonmetastatic breast cancer or diagnosis of nonmetastatic prostate cancer 2. measurement of bone mineral density by dual energy x-ray absorptiometry (dexa) within 6 months of enrollment into study. 3. patients of all ages are eligible but need to qualify for standard dexa screening 4. patients of all performance status are eligible 5. patients are able to give informed consent exclusion criteria 1. patients previously diagnosed or treated for osteoporosis/osteopenia 2. stage iv cancer

Keywords: breast cancer prostate cancer osteopenia osteoporosis secondary causes of bone loss
the role of personal identity in psychotic symptoms: a study with the repertory grid technique

Conditions: Schizophrenia; Psychotic Disorders; Self

Summary: personal identity is being recently recognized as a core element for mental health disorders, with relevant clinical implications. however, scarcity of data exists on its role in schizophrenia and related disorders. the repertory grid (rgt), a technique derived from personal construct theory, has been used in different clinical and non-clinical contexts for the study of the construction perception of self and others, to appreciate aspects of interpersonal construing such as polarization and differentiation (unidimensional thinking) or self-construction.and our study aims to explore the potential influence of the structure of personal identity and of other relevant cognitive factors (social cognition, metacognition, neurocognition) in positive and negative symptoms in people suffering schizophrenia and related disorders.

over recent years, the importance of the sense of self and personal identity in psychopathology and its treatment has been highlighted. several studies inspired in the personal construct psychology framework have found a variety of identity characteristics in clinical conditions such as depression or eating disorders, but the evidence in schizophrenia and other psychotic related disorders is scarce. in addition, current psychological models of positive and negative symptoms highlight the influence of neurocognition, social cognition and self-concepts in the development and maintenance of psychotic experiences. despite the recognized need of person-centered approaches to understand psychopathology processes in psychosis, psychological models for explaining psychotic symptoms have not explored sufficiently the role of this kind of person-centered measures. aim 1. to examine the influence of the structure of personal identity and other relevant cognitive factors in positive and negative symptoms hypotheses 1. positive symptoms will be influenced by dichotomous thinking style and construction of self as measured with the rgt. 2. negative symptoms will be affected by the richness of the construct system as measured with the rgt.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia, psychotic disorder not otherwise specified, delusional disorder, schizoaffective disorder, brief psychotic disorder, or schizophreniform disorder * age between 18 and 60 years. * patients from outpatient mental health units exclusion criteria: * traumatic brain injury, dementia, or intellectual disability (pre-morbid iq \<70) * current substance dependence

Keywords: personal identity personal constructs
four methods of pre-oxygenation

Conditions: Respiratory Failure

Summary: four methods of preoxygenation will be compared in healthy volunteers

after informed consent, each volunteer will undergo the following techniques: simple mask at "flush" flow (40-60 l/min) non-rebreather mask at 15 l/min non-rebreather mask at 60 l/min bag valve mask with one way exhalation valve at 15 l/min after 3 minutes, the exhaled oxygen will be measured with an oxygen sensor

Eligibility criteria:
inclusion criteria: * over 18 years old exclusion criteria: * any active respiratory pathology (asthma, chronic obstructive pulmonary disease, other lung disease, smoking history more than 5 years) * pregnant
urinary procedures performed by gynecologists, results and learning curves.

Conditions: Gynecologic Cancer; Endometriosis

Summary: urinary procedures such as placing a jj catheter, performing a psoic bladder, a bricker technique or even a partial cystectomy are relatively frequent procedures in the context of the surgical management of gynecological cancer or endometriosis in order to obtain maximum reduction in oncology, or to overcome all endometriotic lesions when they affect the urinary tract. however, gynecological surgeons are not always trained in these specific procedures, the learning of which is crucial in the optimal management of these patients. the aim of the research is to describe the surgical experience in terms of urinary actions (jj catheter placement, psoic bladder, bricker technique, cystectomy) over the past 10 years and determine a learning curve for a surgical team made up of only gynecological surgeons


Eligibility criteria:
inclusion criteria: * adult woman (≥18 years old) * woman with gynecological cancer or endometriosis, having undergone surgery between 01/01/2010 and 04/30/2021 at strasbourg university hospital * with the performance of urological procedures during the operation performed by a surgical team composed of a gynecological surgeon * woman who did not express her opposition to the reuse of her data for the purposes of this research. exclusion criteria: * woman who expressed her opposition to participating in the study * surgery performed by a team of surgeons not composed exclusively of gynecologists

Keywords: gynecologic cancer endometriosis
phase iii randomized, double-blind, placebo-controlled study of dehydroepiandrosterone in women with active systemic lupus erythematosus

Conditions: Systemic Lupus Erythematosus

Summary: objectives: i. evaluate the safety and efficacy of synthetic dehydroepiandrosterone, gl701, in women with active systemic lupus erythematosus.

protocol outline: this is a randomized study. patients are stratified by participating institution. patients are randomly assigned to daily oral dehydroepiandrosterone or placebo for 52 weeks. patients are evaluated every 13 weeks on study and return for a follow-up 6 weeks after completion of therapy. concurrent therapy with estrogen replacement and stable doses of prednisone, azathioprine, methotrexate (with folate supplementation), hydroxychloroquine, and nonsteroidal anti-inflammatory drugs is allowed. other investigational medications and immunosuppressants are prohibited.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- systemic lupus erythematosus by 1982 american college of rheumatology criteria diagnosed for at least 6 months systemic lupus activity measure score at least 7 points for erythrocyte sedimentation rate excluded sledai score of greater than 2 at both screening and qualifying visits --prior/concurrent therapy-- no prior participation in any dehydroepiandrosterone (dhea) study no investigational agent within the longer of 30 days or 10 half-lives of the agent prednisone (or equivalent) dose 0 to 10 mg/day unchanged for at least 6 weeks prior to entry at least 3 months since immunosuppressants other than azathioprine and methotrexate, including: * dhea * adrenocorticotropin hormone * androgens * cyclophosphamide * cyclosporine * immune globulin at least 6 weeks since change in azathioprine, methotrexate, or hydroxychloroquine --patient characteristics-- renal: no requirement for hemodialysis cardiovascular: no serious abnormality on electrocardiogram other: * no hypersensitivity to dhea or inactive ingredients in gl701 formulation, i.e., cornstarch, lactose, or magnesium stearate * no history of breast cancer or reproductive tract malignancy * cervical carcinoma eligible if surgically cured, i.e., no evidence of disease for 5 years * no condition that would prevent compliance or follow-up, e.g.: alcoholism drug addiction acute withdrawal from chemical dependency * psychiatric disease * no pregnant or nursing women * negative pregnancy test required of fertile women * reliable contraception required of fertile women * no estrogen-containing oral contraceptives on study * at least 3 weeks since estrogen-containing oral contraceptives

Keywords: arthritis & connective tissue diseases immunologic disorders and infectious disorders rare disease systemic lupus erythematosus